The National Office of Animal Health (NOAH) has responded to the Government’s announcement of a review into the over-the-counter (AVM-GSL) classification of pet parasite control products containing fipronil and imidacloprid.
NOAH said that parasitic infections remain a significant risk to companion animals and, in certain instances, humans. Ready access to effective, regulated parasite control products plays a vital role in preventing disease, supporting animal welfare, and reducing the risk of zoonotic transmission.
At the same time, pet owners across the UK are facing ongoing cost of living pressures. Affordability is a critical factor in ensuring animals receive the care they need. The Competition and Markets Authority (CMA) has already highlighted the importance of improving affordability and transparency in the veterinary sector, making clear that animal healthcare should be made more accessible, not more expensive.
Dawn Howard, NOAH chief executive, said: “Parasite control is a cornerstone of responsible pet ownership. While we support a thorough and transparent review, it is essential that decisions are grounded in sound science and a full understanding of the real-world impacts on animal health and welfare.
“Pet owners are already under financial pressure, and affordability directly influences whether animals receive the treatments they need. Any move that increases costs or reduces access risks leaving more animals unprotected.”
Mrs Howard continued: “AVM-GSL products provide a convenient and effective route for pet owners to protect animals from parasites. Removing or restricting that access could create further barriers to timely treatment, particularly for those who are already unable to access veterinary services.”
NOAH is already concerned about the practical realities of access to veterinary services. The organisation said there are over two million cats and dogs in the UK that are not registered with a veterinary practice, in many cases because local practices are not accepting new clients.
Removing or restricting the AVM-GSL route could further limit access to essential parasite control, effectively narrowing one of the few remaining pathways for some owners to protect their animals’ health.
NOAH added that Available environmental monitoring data show declining trends in imidacloprid concentrations in UK surface waters, with evidence indicating that sources are multiple and not limited to veterinary medicines.
Mrs Howard said: “Importantly, this downward trend has occurred without changes to the current distribution and classification of companion animal parasiticides, suggesting that progress can be achieved without disproportionate regulatory intervention.
“The animal health industry takes environmental protection seriously and is fully committed to working constructively with Government and regulators to support responsible use of veterinary medicines. Through our campaign, Use It Right, Treat Them Right, the industry is actively working to improve awareness of correct application; adherence to label warnings, including advice on bathing; swimming and disposal; and the wider importance of stewardship.”
